INTRODUCTION
Obesity-associated liver steatosis referred to as nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of neutral triglyceride droplets within hepatocytes (1, 2) . Liver lipidomic analyses in NAFLD have demonstrated increased diacylglycerol, free cholesterol, and lysophosphatidylcholine (LPC), in addition to the morphologically obvious triglyceride (Table 1) (3) (4) (5) (6) (7) . A host of metabolic perturbations, dietary factors, genetic influences and environmental determinants pre-dispose to steatosis, and these have been comprehensively reviewed elsewhere (8) (9) (10) (11) . A subset of NAFLD patients develops progressive liver injury, termed nonalcoholic steatohepatitis (NASH), characterized histologically by hepatic inflammation, fibrosis and cirrhosis (12, 13) and molecularly by hepatocyte apoptosis (12) . This group is clinically relevant due to the risks of liver failure, hepatocellular carcinoma and the need for lifesaving liver transplantation (2) . Mechanistic studies of lipotoxicity have thus focused on NASH, due to its progressive nature and associated clinical risks.
The lipids that can activate these processes are defined as toxic lipids in NASH pathogenesis.
These toxic lipids can activate proapoptotic signaling and myriad stress responses in hepatocytes (14) (15) (16) (17) (18) (19) (20) .
In general, the saturated free fatty acids, palmitate and stearate, are directly cytotoxic, whereas the monounsaturated free fatty acids, such as oleate and palmitoleate, may protect from saturated fatty acidinduced toxicity, though the latter may impart sensitization to death receptor mediated apoptosis (14, 15, 21) . Furthermore, palmitate can induce the formation of both ceramide and LPC (6, 16, 22) . Ceramide can be directly synthesized from palmitate via the de novo pathway at the endoplasmic reticulum (ER) (22, 23) . LPC is formed via phospholipase A2 action on phosphatidylcholine, which in turn is derived from diacylglycerol; palmitate-induced diacylglycerol accumulation thus indirectly leads to LPC formation ( Figure 1 ) (6) . LPC can activate proapoptotic signaling akin to palmitate (6, 16) , and lead to extracellular vesicle release (24) . Palmitate-derived C16 ceramide is associated with insulin resistance and steatohepatitis (25, 26 ), and at a cellular level can induce extracellular vesicle release (27) . In this review, we discuss the signaling through which these lipids lead to cell death and inflammation (15, 28) .
Short of causing cell death, lipid overload leads to ballooned hepatocytes (29) , which do not progress to by guest, on November 10, 2017 www.jlr.org
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Death receptors expressed in the liver have been considered as potential mediators of hepatic lipotoxicity (43) . Liver expression of death receptor Fas is significantly increased in patients with NAFLD compared to healthy controls (44, 45) . In animal models of NAFLD, lipid-loaded hepatocytes were greatly susceptible to Fas-mediated apoptosis upon administration of anti-Fas antibody (46, 47) .
Nevertheless, there are no in vivo studies implicating Fas in the development of NASH. Also, hepatocytes isolated from Fas-deficient lpr mice readily underwent palmitate-induced lipoapoptosis comparable to wild-type cells, suggesting that apoptosis induced by toxic lipids is not dependent on Fas (18) . Similar to Fas, TNFR1 is also upregulated in liver of NASH patients (48, 49) . TNFR1 and its cognate ligand TNFα play important role in proinflammatory signaling, development of insulin resistance and, perhaps, steatosis; however they are not directly implicated in mediating lipoapoptosis in the liver (43) .
Among the death receptors, TRAIL-R2 (also known as DR5) appears to be a major mediator of lipotoxicity in hepatocytes (18, 50) . Again, liver expression of TRAIL-R2 is significantly increased in patients with NASH as well as in a murine nutrient-excess model of NASH (51, 52) . Palmitate-induced apoptosis is significantly decreased in primary hepatocytes and hepatocellular carcinoma cell line lacking TRAIL-R2, but not TRAIL-R1 (18) . In wild-type hepatocytes, palmitate treatment increases TRAIL-R2 expression and changes organization of plasma membrane domains causing clustering and ligandindependent activation of TRAIL-R2, leading to caspase 8-dependent cell death ( Figure 3 ) (18) .
Increased expression of TRAIL-R2, but not other death receptors, and ligand-independent activation of the TRAIL-R2 causing caspase 8-dependent apoptosis have recently been also described in cells with persistent ER stress (53, 54) . Because saturated fatty acids also cause ER stress (see below), this TRAIL-R2 proapoptotic signaling may also contribute to free fatty acid-induced lipoapoptosis. It is important to note that palmitate also upregulates proapoptotic proteins such as p53-upregulated modulator of apoptosis (PUMA) and Bim, which contribute to lipoapoptosis in the context of TRAIL-R2 activation (see below).
Upregulation of these proapoptotic proteins may be critical for lipoapoptosis as TRAIL receptor liganddependent activation is harmless to healthy hepatocytes but is cytotoxic to steatotic hepatocytes both in by guest, on November 10, 2017 www.jlr.org Downloaded from vitro and in vivo (14, 51, 55) . Thus, upregulation of proapoptotic proteins by palmitate or LPC in hepatocytes is key to their sensitization to apoptosis. Finally, in a murine model of western diet-induced NASH (56), TRAIL receptor deficiency remarkably protects against hepatocyte apoptosis and all other associated pathogenic features of NASH, such as liver injury, inflammation and fibrosis (50) . Altogether, these studies suggest that TRAIL receptor signaling plays a key role in hepatocyte lipotoxicity.
Engagement of Bcl-2 Proteins by Free Fatty Acids
Many proapoptotic signaling cascades including those initiated by death receptors converge on the mitochondria triggering mitochondrial outer membrane permeabilization (MOMP) (57) . The MOMP results in egress of proapoptotic mediators such as cytochrome c and second mitochondrial activator of apoptosis (SMAC) into the cytosol where they promote activation of effector caspases culminating in cellular disassembly. MOMP is regulated by proteins of the Bcl-2 family (57). Anti-apoptotic members include Bcl-2, Bcl-xL, and Mcl-1; these proteins act to prevent MOMP. The proapoptotic molecules are Bax and Bak which oligomerize to induce the MOMP. The family of BH3-only proteins act as biosensors of proapoptotic stimuli, and induce MOMP either by deactivating (i.e., Bmf, Bad, Hrk, Bik) the anti-apoptotic proteins or directly activating Bax or Bak (i.e., Bim, Bid, Noxa, PUMA) (57, 58).
Lipotoxic stimuli have been shown to modulate expression and function of Bcl-2 family proteins in hepatocytes (16) (17) (18) (19) (20) 59 ). In particular, PUMA is induced by palmitate and LPC in cultured hepatocytes and hepatocyte-derived cell lines, and hepatocytes genetically deficient in PUMA are resistant to lipoapoptosis (20) . Thus, PUMA is likely a key sensitizer of hepatocytes to lipoapoptosis. PUMA appears to be upregulated by multiple mechanisms during palmitate-induced hepatocyte lipoapoptosis.
For example, an ER stress pathway involving CAAT/enhancer binding homologous protein (CHOP) and activator protein (AP)-1, the latter activated by JNK signaling pathways, potently induces PUMA expression by enhancing its transcription (17, 20) . AP-1 and CHOP form a transcription complex inducing PUMA expression following incubation of hepatocytes with palmitate. Loss of miR-296-5p during palmitate-induced hepatocyte apoptosis may also contribute to upregulation of PUMA expression by enhancing its translation (19) . Interestingly, miR-296-5p is reduced in human liver specimens from by guest, on November 10, 2017 www.jlr.org Downloaded from patients with NASH, and varies inversely with PUMA mRNA levels in these specimens (19) . These observations imply that this mechanism of enhanced PUMA protein expression during lipotoxicity is germane to human NASH. Cellular levels of Kelch-like ECH-associated protein 1 (Keap1) also regulate hepatocyte expression of PUMA (59) . Keap1 is an adaptor protein for E3 ligases and initiates the proteasomal degradation of several proteins (e.g. nuclear factor (erythroid-derived 2)-like 2, Nrf2).
Hepatocyte-specific genetic deletion of Keap1 is associated with increased liver steatosis and greater sensitivity of hepatocytes to palmitate-mediated lipoapoptosis due to increased expression of both Bim and PUMA (59) . Loss of Keap1 during palmitate treatment of hepatocytes appears to be via autophagic degradation of Keap1. Thus, multiple signaling networks initiated by lipotoxic stress in hepatocytes converge to enhance PUMA expression, which sensitizes the cells to apoptosis (Figure 3 ).
Bim may also be upregulated by lipotoxic stimuli through activation of the transcription factor FoxO3a (34).
Lipotoxic stimuli such as saturated fatty acids activate phosphatases which dephosphorylate FoxO3a promoting its translocation into the nucleus and induction of Bim transcription (60 It has long been recognized that unsaturated free fatty acids antagonize the proapoptotic effects of saturated fatty acids in a variety of cell types (21, 62, 63) . Indeed, the monounsaturated free fatty acid palmitoleate is quite cytoprotective during palmitate treatment of hepatocytes (21 (64) . In both these studies the combination of a monounsaturated fatty acid with palmitate mitigated palmitate-induced cell death, while enhancing triglyceride deposition.
The role of Bcl-2 proteins in liver lipotoxicity warrants further study. Important insights will be gained from their study in animal models of NASH. As Bax or Bak pharmacologic inhibitors become available they will also help define the role of mitochondrial apoptosis in models of NASH. Along these lines, we remain intrigued that delivering miR-296-5p to the liver using nanoparticles could also be salutary in human NASH by preventing PUMA upregulation.
Free Fatty Acid-Induced MLK3 and JNK signaling MLK3, a ubiquitously expressed member of a family of serine/threonine protein kinases that function in a phospho-relay module to control the activity of downstream mitogen-activated protein kinases (MAPK) (65, 66) , is implicated in NASH pathogenesis (24) and palmitate-induced JNK activation (67, 68) . We reported that MLK3 genetic deficiency in a murine model of diet-induced obesity, insulin resistance and NASH is protective against disease progression by decreasing liver steatosis, injury, inflammation and fibrosis (24) . These effects were accompanied by a reduction in the activating phosphorylation of JNK in the liver (24) .
JNK is a member of the MAPK family (69) . Of the three JNK genes, JNK1 and JNK2 are expressed in the liver (69) . JNK signaling is activated in dietary and genetic animal models of NASH (70) (71) (72) , and in human NASH (20, 73) . NASH-associated JNK activation was reported in both hepatocytes and macrophages, causing apoptosis and liver inflammation, respectively (74, 75) . Interestingly, JNK in macrophages is required for tissue infiltration and pro-inflammatory polarization (28) . Both JNK1 and JNK2 have been implicated in insulin resistance and steatohepatitis (69) . In a mouse model of obesity, JNK phosphorylates insulin receptor substrate-1, suppressing insulin receptor signaling, and inducing by guest, on November 10, 2017
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insulin resistance (76) . JNK is directly implicated in inhibition of fatty acid oxidation and susceptibility to steatosis by its hepatic regulation of peroxisome proliferator-activated receptor (PPAR) α (77) . JNKinduced repression of PPARα suppresses the production of fibroblast growth factor 21, consequently inhibiting mitochondrial and peroxisomal fat oxidation and ketogenesis (77) . The specific roles of JNK1
and JNK2 in NASH are divergent, depending on the dietary model used (71, 72) . JNK1 mediates mouse steatohepatitis due to a diet deficient in methionine and choline (71), whereas, when mice are fed a high fat diet, JNK1 predominantly mediates steatosis and liver injury, though JNK2 contributes to proapoptotic protein expression (72) . Because JNK1 knockout mice are resistant to obesity while on a high fat diet, the improved metabolic and hepatic profiles cannot be differentiated from the effects of minimal weight gain (72) . Notably, the anti-obesity effect of genetic JNK1 deletion may be mediated via its signaling in the pituitary gland (78) .
At a cellular level, similar to the in vivo data, JNK1 appears to be the predominant form (75, 79, 80) . In addition, JNK induces TRAIL-R2 expression, which sensitizes steatotic hepatocytes to TRAIL-mediated hepatotoxicity (14, 81) . We speculate that inhibition of this kinase cascade via proximal inhibition of MLK3, or more distally of JNK, is a potential therapeutic strategy for the treatment of human NASH.
Lysophosphatidylcholine-Induced Proapoptotic Signaling
LPC is a phospholipid generated from phosphatidylcholine by partial hydrolysis, which removes one of the fatty acid groups. This reaction is usually catalyzed by phospholipase A2 (PLA2) (6, 28) . LPC is also formed in the plasma by lecithin-cholesterol acyltransferase activity (82) . Thus, hepatocytes can be exposed to LPC derived from at least two sources. These are extracellular plasma LPC and LPC by guest, on November 10, 2017
www.jlr.org Downloaded from generated intracellularly within hepatocytes, via PLA2 activity. The relative proportion of these two pathways to LPC accumulation in hepatocytes in vivo remains to be clarified.
LPC has been implicated in mediating free fatty acid-induced lipotoxicity in hepatocytes (6, 16).
Han et al. observed that conversion products of palmitate, rather than palmitate itself, induced hepatocyte lipoapoptosis (6) . Interestingly, in this study, the metabolism of palmitate to lipid intermediates in the sphingolipid-ceramide pathway was not responsible for hepatocyte lipoapoptosis. However, hepatocytes
were protected against palmitate-induced apoptosis when the conversion of palmitate was blocked by triacsin C, an acyl-CoA synthetase inhibitor. In addition, palmitate-induced cell death was also significantly attenuated by inhibition of PLA2, suggesting that formation of LPC plays a principal role in palmitate lipotoxicity. In line with these observations, LPC intracellular levels in cultured hepatocytes increase proportionally to the concentration of palmitate treatment (16) . Conversely, inhibition of PLA2
in hepatocytes leads to decreased fatty acid uptake and decreased concentration of intracellular LPC (83) .
Hepatocyte treatment with exogenous LPC readily induces lipoapoptosis in primary hepatocytes and human hepatocellular carcinoma cell lines (16, 33) . Whether exogenous LPC is taken up by cells or acts at the plasma membrane level to induce signaling is not well understood. In the study by Han et al., LPCinduced lipoapoptosis appeared to be dependent on an unidentified G protein-coupled receptor (6).
Kakisaka et al. found that hepatocyte treatment with exogenous LPC induce JNK activation, similarly to palmitate (16) . In a JNK-dependent manner, LPC also increased the expression of CHOP, an effector protein of ER stress response (16) . CHOP-mediated upregulation of PUMA, a potent proapoptotic BH3-only protein of the Bcl-2 family, then triggered caspase-dependent cell death. Being an intracellular metabolite, exogenous LPC treatment might be less physiologic than treatment with palmitate itself. On the other hand, LPC-induced lipoapoptosis is dependent on mechanisms largely indistinguishable from palmitate-induced lipoapoptosis, consistent with the notion that LPC mediates palmitate-induce lipotoxicity in hepatocytes.
Finally, the potential role of LPC in human disease has been also highlighted by the accumulation of this lipid in the liver of NASH patients (3, 6) . The total phospholipid content in the NASH liver appears to be decreased and therefore the reduced phospholipid/LPC ratio may indicate an increase in phospholipase A2 activity (3, 83) . Consistent with this notion, PLA2 deletion in ob/ob mice, a genetic model of NAFLD, significantly decreased the development of spontaneous liver steatosis in (84) . Future studies will need to confirm whether PLA2 activity is increased during NASH.
Ceramides in NASH
Ceramides are sphingolipids that function as lipid second messengers. Ceramide is generated at the ER via condensation of palmitoyl-CoA and serine, in a reaction catalyzed by serine palmitoyltransferase (SPT), to form 3-ketosphinganine, which is converted to ceramide by a series of enzymatic steps, in the de novo ceramide synthesis pathway (22) . of a large cohort of obese subjects (25) . They subsequently deleted CerS6 in mice. These mice were protected from diet-induced obesity, insulin resistance and hepatosteatosis. Interestingly, CerS6 deleted hepatocytes exhibited increased palmitate oxidation, and mice lacking CerS6 in brown adipose tissue also showed increased lipid oxidation, suggesting that C16:0 ceramide generated by CerS6 inhibits lipid utilization in the liver and brown adipose tissue in obesity. Conversely, inhibition of ceramide synthesis by myriocin, or degradation of ceramides by transgenic overexpression of acid ceramidases, improved hepatic steatosis (87) . The expression of a fatty acid transporter, CD36, was reduced in these livers, suggesting that ceramide promotes hepatic steatosis by increasing hepatocyte uptake of fatty acids.
In cultured hepatocytes, palmitate-induced apoptosis is associated with increased cellular ceramide concentrations (88) . Studies that have examined the effects of inhibition of ceramide synthesis on palmitate-induced lipoapoptosis have given mixed results (6, 88) . Sphingomyelinases and the salvage pathway of ceramide synthesis are linked to death receptor-induced apoptosis in hepatocytes (89) (90) (91) . Fas ligand-activated Fas signaling led to acid sphingomyelinase-dependent ceramide synthesis with subsequent formation of reactive oxygen species in rat hepatocytes (89) . In mouse and rat hepatocytes undergoing TNFα-induced apoptosis, endogenous C16 ceramide levels were found to be elevated (90) .
Furthermore, an increase in lysosomal ceramide, and sphingosine was reported in liver cell lines undergoing apoptosis via TNFα/cyclohexamide-induced lysosomal permeabilization (91). This was mediated by both acid sphingomyelinase and neutral sphingomyelinase. Whether ceramides directly alter the apoptotic pathway or machinery in palmitate-loaded hepatocytes remains to be elucidated.
Lipid-Activated ER Stress Response
The unfolded protein response (UPR), mediated by three transmembrane ER proteins, inositol requiring enzyme-1 alpha (IRE1α), protein kinase like-ER kinase (PERK), and activating transcription factor (ATF) 6α is increasingly linked to both lipid metabolism and lipotoxic signaling (92) . Given that this topic is covered in another review in this series, we will limit our discussion to the context of palmitate or LPCmediated hepatocyte apoptosis. Palmitate-induced hepatocyte apoptosis is mediated, in part, by ER stress-induced activation of CHOP (18) . Moreover, CHOP upregulates the proapoptotic protein PUMA and the cell surface death receptor TRAIL-R2 (17, 18) , though additional pathways may play a role (93) .
Surprisingly, CHOP knockout mice were sensitized to the development of high fat diet-induced by guest, on November 10, 2017
www.jlr.org Downloaded from steatohepatitis, and methionine-deficient choline-deficient diet-induced steatohepatitis (94) . This was due to a dominant in vivo effect of CHOP deletion in macrophages, which allowed the persistence and accumulation of macrophages in the liver, thus increasing the proinflammatory milieu (94).
SUB-LETHAL INFLAMMATION and INJURY
Palmitate can activate signaling events in macrophages that either occur independently of cell death or precede cell death. In macrophages, palmitate and other saturated free fatty acids can directly activate toll-like receptors (TLRs), with subsequent activation of the proinflammatory transcription factor nuclear factor-κB (NF-κB). This non-lethal proinflammatory signaling is discussed below. Palmitate can activate several kinase pathways in myriad cell types (95-100). Palmitate-induced activation of protein kinase C (PKC), protein kinase B (PKB), and double-stranded RNA-dependent protein kinase (PKR) are well studied in cell types other than hepatocytes and therefore are only briefly mentioned. Furthermore, in recent years, non-lethal proapoptotic signaling events generated in lipotoxic hepatocytes are gaining importance due to improvements in our ability to dissect the signaling events emanating from these stressed steatotic hepatocytes. In this context, we discuss the importance of ballooned hepatocytes and lipotoxic hepatocyte-derived extracellular vesicles.
Free Fatty Acid-Induced TLR and NF-κB Activation
TLRs are a family of pattern recognition receptors, mediators of innate immune responses, that are tightly associated with the detection of pathogen-associated molecular patterns and endogenous damageassociated molecular patterns (DAMPs), including the widely expressed high-mobility group box 1 (HMGB1) (101, 102) . Obesity-associated chronic low-grade inflammation in insulin target tissues is a major contributor to insulin resistance (103) . This inflammation is mediated, at least in part, by saturated fatty acids that stimulate proinflammatory pathways in a TLR4-dependent manner in adipocytes and macrophages (104) . TLR4 signaling leads to the activation of the transcription factors NF-κB and AP-1, resulting in the production of inflammatory cytokines (104) . Furthermore, saturated fatty acids can activate myeloid proinflammatory cells via TLR2/4 and JNK signaling pathways, thereby promoting inflammation and subsequent peripheral insulin resistance (105) . Though endotoxin contamination of bovine serum albumin has been a concern in palmitate-induced TLR4 activation (106), macrophages do activate TLR4 signaling when treated with palmitate without bovine serum albumin (107) . In an elegant study, Pal et al. (108) identified fetuin-A, a liver-derived circulating glycoprotein, as an endogenous ligand that directly links saturated fatty acids to TLR4 activation in adipocytes, leading to NF-κB activation and upregulation of the inflammatory cytokines interleukin-6 and TNF-α, resulting in insulin resistance. Moreover, β cells respond to the palmitate via the TLR4 signaling pathway and produce chemokines that recruit proinflammatory monocytes/macrophages to the islets (109). Depletion of proinflammatory cells protected mice from palmitate-induced β cell dysfunction. In hepatocytes, palmitate-induced HMGB1 release mediates the activation of TLR4 signaling in an autocrine manner, leading to hepatocyte NF-κB activation and cytokine expression (110) . Taken together, these studies provide evidence that palmitate-induced TLR activation in hepatocytes and macrophages enhances the release of inflammatory cytokines, contributes to the development of insulin resistance and progression of NASH, though it is not linked to palmitate-induced hepatocyte apoptosis.
Other Potentially Important Fatty Acid -Induced Signaling Pathways
A number of other signaling pathways have been shown in other tissues to be engaged during lipotoxic stress, but thus far, there is limited evidence that these pathways play a central role in the response to lipid metabolic stress in the liver. Palmitate can activate PKC isoforms in several cell types including pancreatic β cells, adipocytes, skeletal myocytes, and hypothalamic neurons (91, 92, 87, 88, (94) (95) (96) (97) . In pancreatic β cell lines, palmitate-induced activation of PKC induces NADPH oxidase activity and leads to production of reactive oxygen species (111) . In 3T3-L1 adipocytes, in addition to promoting insulin resistance, palmitate activation of PKC-θ signals downstream through JNK and NF-κB (100). In vascular smooth muscle cells, activation of several PKC isoforms was associated with palmitate-induced apoptosis (112) . While oxidative stress and signaling through JNK and NF-κB have been implicated in NASH, the potential contributions of these PKC pathways to NAFLD progression are not well understood.
Conversely, palmitate can inhibit PKB, a key mediator of cellular metabolic responses (113, 114) .
In hepatocytes, palmitate-induced apoptosis was associated with inhibition of PKB activation (115, 116) and decreased insulin-induced PKB phosphorylation (99, 117) . In additional cell types, such as myocytes, insulin resistance due to palmitate is also manifest as PKB inhibition (118) . Whether palmitate inhibition of PKB signaling contributes to progression of NAFLD is not known.
PKR signaling is activated by palmitate in cultured cells including hepatocytes, adipocytes, β cells, and myocytes. Though PKR is convincingly activated by palmitate, its in vivo role is less clear.
While early studies suggested that lipid-induced PKR activation in the liver contributed to insulin resistance (109, 110, 111) , a recent study demonstrated that deletion of PKR in mice did not ameliorate high fat diet-induced hepatic steatosis or glucose metabolism (119) . Furthermore, macrophages from PKR knockout mice had no defects in palmitate-induced proinflammatory signaling. In none of these studies, however, was there clear evidence that induction of the PKR signaling pathway in hepatocytes or Kupffer cells contributed to the development of NASH.
Ballooned Hepatocytes
Hepatocytes with ballooning degeneration are a prominent histopathological feature of lipotoxic liver injury. Indeed, the magnitude of hepatocellular ballooning correlates with NASH severity and is used to calculate the disease activity score (120, 121) . Tunicamycin-induced ER stress also enhances expression and secretion of sonic hedgehog by hepatocytes (31) . In these studies, sonic hedgehog generated by hepatocytes has been suggested as a paracrine profibrotic factor for stromal cells, which are thought to be the major hedgehog-responsive cells. Hepatocytes also express components of the hedgehog signaling cascade, e.g. plasma membrane receptor smoothened, and may represent an important target of hedgehog signaling during lipotoxicity (51) . Activation of Gli1, a transcription factor mediating canonical hedgehog signaling, increased production of osteopontin by hepatocytes, which in turn promoted macrophage-associated proinflammatory response in a paracrine fashion (124) . Finally, inhibition of hedgehog signaling by pharmacological inhibitors of smoothened (vismodegib and erismodegib) or genetic deletion of smoothened in the liver parenchyma prevents liver injury, inflammation and fibrosis in mouse models of NAFLD and NASH (51, 124) .
Extracellular Vesicles and Inflammation
Cells release diverse types of membrane-bound nanoparticles into the extracellular milieu. These can be of endosomal or plasma membrane origin, termed exosomes or microvesicles, respectively, and EVs in mouse models of liver ischemia reperfusion injury (126) and NASH (33, 127) .
EVs have been implicated in lipotoxic signaling in several recent studies (Figure 4) . One of the first reports of their significance in NASH was the observation that repeated injections of EVs isolated from the serum of high fat diet-fed mice to chow diet-fed mice resulted in hepatic inflammation and promoted the development of fatty liver disease (128) . Later, several studies have clearly demonstrated that EV release from hepatocytes is significantly increased upon treatment with lipids such as palmitate, LPC, and even ceramide loading of cells (27, 33, 127, 129) . Consistent with the emerging literature, lipotoxic EVs are heterogeneous. This applies to the mechanisms of biogenesis and release, cargo contained therein, and effects on target cells. For example, LPC-mediated EV release from hepatocytes is MLK3-dependent, and MLK3 regulates the chemotactic cargo of the EVs (129) . Specifically, the abundance of the potent chemokine C-X-C motif ligand 10 (CXCL10) is significantly reduced in LPCstimulated MLK3-deficient hepatocytes or by pharmacologic inhibition of MLK3. Likewise, MLK3 knockout mice fed a high fat, fructose and cholesterol diet (56) have reduced CXCL10 levels in plasma EVs (129) . This, in turn, is associated with hepatoprotection against diet-induced liver injury and inflammation.
LPC-stimulated hepatocyte EVs appear to originate mainly from the plasma membrane, as their release is sensitive to inhibition by fasudil, an inhibitor of Rho-associated coiled-coil containing protein kinase 1 (ROCK1) (33) . This phenomenon precedes cell death, however, requires activation of the TRAIL receptor proapoptotic pathway, consisting of the TRAIL receptor → caspase 8 → caspase 3 signaling cascade. These EVs are biologically potent as they induce macrophage activation, partly by a TRAIL-dependent mechanism. Consistent with these in vitro data, the ROCK1 inhibitor fasudil decreased NASH-induced circulating EVs, which was associated with a reduction in liver injury, inflammation and fibrosis (33) .
EVs derived from lipotoxic hepatocytes also mediate angiogenesis (127) . Neovascularization is an important pathological feature of NASH and correlates with fibrosis severity (127) . Lipotoxic EVs were laden with vanin 1, an ectoenzyme with known cell migration and adherence properties. There are likely multiple mediators of macrophage chemotaxis and activation within the lipotoxic hepatocyte EVs. In fact, our EV protein mass spectrometry analysis demonstrated that these EVs contain many DAMPs (32) . These DAMP are known to activate inflammatory responses in mammalians (131) .
The role of DAMP-enriched EVs as potential macrophage activators and their regulatory relationship merits further studies.
REFLECTION and VISION
What have we learned about hepatic lipotoxicity? Considerable information has been gleaned from in vitro and in vivo model systems regarding hepatic lipotoxicity. We have reviewed above what we believe are the significant observations from both a scientific and clinical perspective. The best information in humans suggests that triglycerides in hepatic steatosis are derived 60% from circulating free fatty acids, 26% from hepatic de novo lipogenesis and 14% from the diet (132) . Moreover, despite the clinical fascination with fat in the liver, we now understand the formation of neutral triglycerides is not injurious to the liver and likely represents both an evolutionary conserved pathway for fatty acid storage and also a detoxification pathway for saturated free fatty acids (64, (133) (134) (135) (136) . Indeed, inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage in obese mice with NASH (136) . This information supports the use of free fatty acids to study lipotoxicity in vitro. We have learned that NASH is a very proapoptotic disease (44) , and inhibition of apoptosis may well be therapeutic in this disease (137) . Consistent with these observations, palmitate and stearate induce robust apoptosis in hepatocytes (75); saturated fatty acids are more toxic than unsaturated fatty acids, but even unsaturated fatty acids such as oleate sensitize hepatocytes to death receptor mediated apoptosis (14, 46) . The role of ER stress in mediating lipotoxic events has also been clarified in a multitude of observations (38, 138) . Thus, the role of free fatty acids in mediating primary hepatocyte apoptosis is clear and the relevance of this model to human NASH has been established. Nonetheless, primary hepatocyte lipotoxicity is likely insufficient to cause hepatic damage and cirrhosis, and likely progressive hepatic injury also requires activation of the innate immune system, especially macrophages (139) . For example, inhibiting macrophage recruitment into the liver is salutary in a murine model of NASH (32) . This information has led to the following working framework: the insulin resistance of obesity results in a surfeit of circulating free fatty acids which inundate the liver, resulting in free fatty acid-mediated ER stress, apoptosis and inflammation culminating in human NASH.
What are the current unanswered questions? There are myriad unanswered questions in NASH pathogenesis and therapy, of which we will discuss two major avenues of future pursuit. First, considerable data suggest that hepatic farnesoid X receptor agonists are beneficial in human NASH (140) .
We need to understand how these agonists disrupt hepatocyte apoptosis or render free fatty acids nontoxic. Such an understanding may provide insight into better therapeutic strategies for human NASH.
Second, we need to understand how lipotoxicity promotes macrophage-associated inflammation in the liver. In keeping with this, we need to test if the lipotoxic liver secretes molecules which are directly 
